The National Institute of Health and Care Excellence (NICE) has provided a final positive recommendation for the use of Eylea on adults for treating visual impairment due to myopic chorodial neovascularisation (mCNV).
Pathological myopia, also known as severe near sightedness, affects 3% of the global population. Of this number, CNV occurs in an estimated 5–10% of patients. The long-term prognosis for CNV is poor, with statistics showing that 90% of patients reach the threshold for ‘legal blindness’ within five years of diagnosis.
Commenting on the NICE approval, CEO of Bayer UK and Ireland, Lars Bruening said: "We are pleased that NICE has recognised the value of Eylea and the benefits that it can bring patients and the clinical community. We are committed to ensuring that all eligible patients have access to Eylea in line with market authorisation so it is great news for patients with mCNV in England and Wales who will have access to this effective treatment as soon as it is adopted by policy makers."
Eylea is already licensed in the UK for treating age-related macular degeneration, visual impairment due to macular oedema secondary to central retinal vein occlusion and visual impairment due to macular oedema secondary to branch retinal vein occlusion.